{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["LY294002", "apoptosis", "breast cancer", "cell cycle", "synergism", "tamoxifen"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32722075", "DateCompleted": {"Year": "2021", "Month": "03", "Day": "01"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "12"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "07", "Day": "24"}], "Language": ["eng"], "ELocationID": ["3355", "10.3390/molecules25153355"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "25", "Issue": "15", "PubDate": {"Year": "2020", "Month": "Jul", "Day": "24"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Tamoxifen and the PI3K Inhibitor: LY294002 Synergistically Induce Apoptosis and Cell Cycle Arrest in Breast Cancer MCF-7 Cells.", "Abstract": {"AbstractText": ["Breast cancer is considered as one of the most aggressive types of cancer. Acquired therapeutic resistance is the major cause of chemotherapy failure in breast cancer patients. To overcome this resistance and to improve the efficacy of treatment, drug combination is employed as a promising approach for this purpose. The synergistic cytotoxic, apoptosis inducing, and cell cycle effects of the combination of LY294002 (LY), a phosphatidylinositide-3-kinase (PI3K) inhibitor, with the traditional cytotoxic anti-estrogen drug tamoxifen (TAM) in breast cancer cells (MCF-7) were investigated. LY and TAM exhibited potent cytotoxic effect on MCF-7 cells with IC<sub>50</sub> values 0.87 \u00b5M and 1.02 \u00b5M. The combination of non-toxic concentration of LY and TAM showed highly significant synergistic interaction as observed from isobologram (IC<sub>50</sub>: 0.17 \u00b5M, combination index: 0.18, colony formation: 9.01%) compared to untreated control. The percentage of early/late apoptosis significantly increased after treatment of MCF-7 cells with LY and TAM combination: 40.3%/28.3% (<i>p</i> < 0.001), compared to LY single treatment (19.8%/11.4%) and TAM single treatment (32.4%/5.9%). In addition, LY and TAM combination induced the apoptotic genes Caspase-3, Caspase-7, and p53, as well as p21 as cell cycle promotor, and significantly downregulated the anti-apoptotic genes Bcl-2 and survivin. The cell cycle assay revealed that the combination induced apoptosis by increasing the pre-G<sub>1</sub>: 28.3% compared to 1.6% of control. pAKT and Cyclin D1 protein expressions were significantly more downregulated by the combination treatment compared to the single drug treatment. The results suggested that the synergistic cytotoxic effect of LY and TAM is achieved by the induction of apoptosis and cell cycle arrest through cyclin D1, pAKT, caspases, and Bcl-2 signaling pathways."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Abdallah", "ForeName": "Mohamed E", "Initials": "ME"}, {"Identifier": ["0000-0001-8398-5412"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt."}], "LastName": "El-Readi", "ForeName": "Mahmoud Zaki", "Initials": "MZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Althubiti", "ForeName": "Mohammad Ahmad", "Initials": "MA"}, {"Identifier": ["0000-0001-7944-2597"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Almaimani", "ForeName": "Riyad Adnan", "Initials": "RA"}, {"Identifier": ["0000-0003-0172-8362"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, Al-Neelain University, Khartoum 11121, Sudan."}], "LastName": "Ismail", "ForeName": "Amar Mohamed", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 7607, Saudi Arabia."}], "LastName": "Idris", "ForeName": "Shakir", "Initials": "S"}, {"Identifier": ["0000-0003-4267-1016"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah 7607, Saudi Arabia."}], "LastName": "Refaat", "ForeName": "Bassem", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Almalki", "ForeName": "Waleed Hassan", "Initials": "WH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Babakr", "ForeName": "Abdullatif Taha", "Initials": "AT"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Mukhtar", "ForeName": "Mohammed H", "Initials": "MH"}, {"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Medicinal and Aromatic Plants Research Institute, National Center for Research, Khartoum 2404, Sudan."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry and Molecular Biology, Faculty of Science and Technology, Al-Neelain University, Khartoum 11121, Sudan."}], "LastName": "Idris", "ForeName": "Omer Fadul", "Initials": "OF"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "CDKN1A protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Chromones"}, {"RegistryNumber": "0", "NameOfSubstance": "Cyclin-Dependent Kinase Inhibitor p21"}, {"RegistryNumber": "0", "NameOfSubstance": "Morpholines"}, {"RegistryNumber": "0", "NameOfSubstance": "TP53 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Tumor Suppressor Protein p53"}, {"RegistryNumber": "094ZI81Y45", "NameOfSubstance": "Tamoxifen"}, {"RegistryNumber": "31M2U1DVID", "NameOfSubstance": "2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one"}, {"RegistryNumber": "EC 3.4.22.-", "NameOfSubstance": "Caspases"}], "MeshHeadingList": [{"QualifierName": ["drug therapy", "metabolism"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": ["metabolism"], "DescriptorName": "Caspases"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle Checkpoints"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Chromones"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cyclin-Dependent Kinase Inhibitor p21"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Synergism"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": ["drug effects"], "DescriptorName": "Gene Expression Regulation, Neoplastic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Inhibitory Concentration 50"}, {"QualifierName": [], "DescriptorName": "MCF-7 Cells"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Morpholines"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Tamoxifen"}, {"QualifierName": ["metabolism"], "DescriptorName": "Tumor Suppressor Protein p53"}], "CoiStatement": "The authors declare no conflict of interest. "}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394\u2013424. doi: 10.3322/caac.21492.", "ArticleIdList": ["10.3322/caac.21492", "30207593"]}, {"Citation": "Al-Shahrani Z., Al-Rawaji A.I., Al-Madouj A.N., Hayder M.S. Cancer Incidence Report Saudi Arabia 2014. Saudi Cancer Registry; Riyadh, Saudi Arabia: 2017. pp. 1\u201381."}, {"Citation": "Sopik V., Sun P., Narod S.A. Predictors of time to death after distant recurrence in breast cancer patients. Breast Cancer Res. Treat. 2019;173:465\u2013474. doi: 10.1007/s10549-018-5002-9.", "ArticleIdList": ["10.1007/s10549-018-5002-9", "30328050"]}, {"Citation": "Alkahtani H.M., Alanazi M.M., Aleanizy F.S., Alqahtani F.Y., Alhoshani A., Alanazi F.E., Almehizia A.A., Abdalla A.N., Alanazi M.G., El-Azab A.S., et al. Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies. Saudi Pharm. J. 2019;27:682\u2013693. doi: 10.1016/j.jsps.2019.04.003.", "ArticleIdList": ["10.1016/j.jsps.2019.04.003", "PMC6598223", "31297023"]}, {"Citation": "Abubakar M., Sung H., Devi R., Guida J., Tang T.S., Pfeiffer R.M., Yang X.R. Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: Analysis of 3012 women from an indigenous Asian population. Breast Cancer Res. 2018;20:114. doi: 10.1186/s13058-018-1033-8.", "ArticleIdList": ["10.1186/s13058-018-1033-8", "PMC6145192", "30227867"]}, {"Citation": "Khalil S., Hatch L., Price C.R., Palakurty S.H., Simoneit E., Radisic A., Pargas A., Shetty I., Lyman M., Couchot P., et al. Addressing Breast Cancer Screening Disparities Among Uninsured and Insured Patients: A Student-Run Free Clinic Initiative. J. Community Health. 2019;45:501\u2013505. doi: 10.1007/s10900-019-00767-x.", "ArticleIdList": ["10.1007/s10900-019-00767-x", "31667647"]}, {"Citation": "Clemons M., Danson S., Howell A. Tamoxifen (\u2018Nolvadex\u2019): A review: Antitumour treatment. Cancer Treat. Rev. 2002;28:165\u2013180. doi: 10.1016/S0305-7372(02)00036-1.", "ArticleIdList": ["10.1016/S0305-7372(02)00036-1", "12363457"]}, {"Citation": "Day C.M., Hickey S.M., Song Y., Plush S.E., Garg S. Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles. Molecules. 2020;25:1182. doi: 10.3390/molecules25051182.", "ArticleIdList": ["10.3390/molecules25051182", "PMC7179425", "32151063"]}, {"Citation": "Silvente-Poirot S., de Medina P., Record M., Poirot M. From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite. Biochimie. 2016;130:109\u2013114. doi: 10.1016/j.biochi.2016.05.016.", "ArticleIdList": ["10.1016/j.biochi.2016.05.016", "27262406"]}, {"Citation": "Wilkes G.M., Barton-Burke M. 2020\u20132021 Oncology Nursing Drug Handbook. Jones & Bartlett Learning; Burlington, MA, USA: 2019."}, {"Citation": "Mohamed K.E., Elamin A. Adherence to endocrine therapy and its relation to disease-free survival among breast cancer patients visiting an out-patient clinic at Khartoum Oncology Hospital, Sudan. J. Eval. Clin. Pract. 2020;1:1\u201313. doi: 10.1111/jep.13373.", "ArticleIdList": ["10.1111/jep.13373", "32101644"]}, {"Citation": "Riggins R.B., Schrecengost R.S., Guerrero M.S., Bouton A.H. Pathways to tamoxifen resistance. Cancer Lett. 2007;256:1\u201324. doi: 10.1016/j.canlet.2007.03.016.", "ArticleIdList": ["10.1016/j.canlet.2007.03.016", "PMC2533271", "17475399"]}, {"Citation": "Liu S., Meng X., Chen H., Liu W., Miller T., Murph M., Lu Y., Zhang F., Gagea M., Arteaga C.L., et al. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014;5:9049. doi: 10.18632/oncotarget.2022.", "ArticleIdList": ["10.18632/oncotarget.2022", "PMC4253418", "24979294"]}, {"Citation": "Chen P., Lee N.V., Hu W., Xu M., Ferre R.A., Lam H., Bergqvist S., Solowiej J., Diehl W., He Y.-A., et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol. Cancer Ther. 2016;15:2273\u20132281. doi: 10.1158/1535-7163.MCT-16-0300.", "ArticleIdList": ["10.1158/1535-7163.MCT-16-0300", "27496135"]}, {"Citation": "Maira S.-M., Stauffer F., Schnell C., Garc\u00eda-Echeverr\u00eda C. PI3K Inhibitors for Cancer Treatment: Where Do We Stand? Portland Press Ltd.; London, UK: 2009.", "ArticleIdList": ["19143644"]}, {"Citation": "Xing C.-G., Zhu B.S., Fan X.Q., Liu H.H., Hou X., Zhao K., Qin Z.H. Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J. Gastroenterol. 2009;15:5044. doi: 10.3748/wjg.15.5044.", "ArticleIdList": ["10.3748/wjg.15.5044", "PMC2768883", "19859997"]}, {"Citation": "Zhao W., Qiu Y., Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm. Sin. B. 2017;7:27\u201337. doi: 10.1016/j.apsb.2016.07.006.", "ArticleIdList": ["10.1016/j.apsb.2016.07.006", "PMC5237710", "28119806"]}, {"Citation": "Rahmani F., Ferns G.A., Talebian S., Nourbakhsh M., Avan A., Shahidsales S. Role of regulatory miRNAs of the PI3K/AKT signaling pathway in the pathogenesis of breast cancer. Gene. 2020;737:144459. doi: 10.1016/j.gene.2020.144459.", "ArticleIdList": ["10.1016/j.gene.2020.144459", "32045660"]}, {"Citation": "Ortega M.A., Fraile-Mart\u00ednez O., As\u00fansolo \u00c1., Buj\u00e1n J., Garc\u00eda-Honduvilla N., Coca S. Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J. Oncol. 2020;2020:9258396. doi: 10.1155/2020/9258396.", "ArticleIdList": ["10.1155/2020/9258396", "PMC7085392", "32211045"]}, {"Citation": "Engelman J.A. Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat. Rev. Cancer. 2009;9:550\u2013562. doi: 10.1038/nrc2664.", "ArticleIdList": ["10.1038/nrc2664", "19629070"]}, {"Citation": "Miller L.A. The National Practitioner Data Bank: A primer for clinicians. J. Perinat. Neonatal Nurs. 2011;25:224\u2013225. doi: 10.1097/JPN.0b013e3182257331.", "ArticleIdList": ["10.1097/JPN.0b013e3182257331", "21825910"]}, {"Citation": "Falasca M. PI3K/Akt signalling pathway specific inhibitors: A novel strategy to sensitize cancer cells to anti-cancer drugs. Curr. Pharm. Des. 2010;16:1410\u20131416. doi: 10.2174/138161210791033950.", "ArticleIdList": ["10.2174/138161210791033950", "20166984"]}, {"Citation": "McKenna M., McGarrigle S., Pidgeon G.P. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. Biochim. Biophys. Acta Rev. Cancer. 2018;1870:185\u2013197. doi: 10.1016/j.bbcan.2018.08.001.", "ArticleIdList": ["10.1016/j.bbcan.2018.08.001", "30318472"]}, {"Citation": "Kanaizumi H., Higashi C., Tanaka Y., Hamada M., Shinzaki W., Azumi T., Hashimoto Y., Inui H., Houjou T., Komoike Y. PI3K/Akt/mTOR signalling pathway activation in patients with ER-positive, metachronous, contralateral breast cancer treated with hormone therapy. Oncol. Lett. 2019;17:1962\u20131968.", "ArticleIdList": ["PMC6341824", "30675261"]}, {"Citation": "Li D., Ji H., Niu X., Yin L., Wang Y., Gu Y., Wang J., Zhou X., Zhang H., Zhang Q. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer Sci. 2020;111:47\u201358. doi: 10.1111/cas.14230.", "ArticleIdList": ["10.1111/cas.14230", "PMC6942430", "31710162"]}, {"Citation": "Jagtap J.C., Parveen D., Shah R.D., Desai A., Bhosale D., Chugh A., Ranade D., Karnik S., Khedkar B., Mathur A., et al. Secretory prostate apoptosis response (Par)-4 sensitizes multicellular spheroids (MCS) of glioblastoma multiforme cells to tamoxifen-induced cell death. FEBS Open Bio. 2015;5:8\u201319. doi: 10.1016/j.fob.2014.11.005.", "ArticleIdList": ["10.1016/j.fob.2014.11.005", "PMC4309838", "25685660"]}, {"Citation": "Ko J.C., Chiu H.C., Syu J.J., Chen C.Y., Jian Y.T., Huang Y.J., Wo T.Y., Jian Y.J., Chang P.Y., Wang T.J., et al. Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells. Biochem. Biophys. Res. Commun. 2015;456:506\u2013512. doi: 10.1016/j.bbrc.2014.11.116.", "ArticleIdList": ["10.1016/j.bbrc.2014.11.116", "25490383"]}, {"Citation": "Ko J.C., Chiu H.C., Syu J.J., Jian Y.J., Chen C.Y., Jian Y.T., Huang Y.J., Wo T.Y., Lin Y.W. Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells. Biochem. Pharmacol. 2014;88:119\u2013127. doi: 10.1016/j.bcp.2014.01.010.", "ArticleIdList": ["10.1016/j.bcp.2014.01.010", "24447935"]}, {"Citation": "Li C., Zhou C., Wang S., Feng Y., Lin W., Lin S., Wang Y., Huang H., Liu P., Mu Y.-G., et al. Sensitization of glioma cells to tamoxifen-induced apoptosis by Pl3-kinase inhibitor through the GSK-3beta/beta-catenin signaling pathway. PLoS ONE. 2011;6:e27053.", "ArticleIdList": ["PMC3203172", "22046442"]}, {"Citation": "Pu X., Storr S.J., Zhang Y., Rakha E.A., Green A.R., Ellis I.O., Martin S.G. Caspase-3 and caspase-8 expression in breast cancer: Caspase-3 is associated with survival. Apoptosis. 2017;22:357\u2013368. doi: 10.1007/s10495-016-1323-5.", "ArticleIdList": ["10.1007/s10495-016-1323-5", "PMC5306438", "27798717"]}, {"Citation": "Nassar A., Lawson D., Cotsonis G., Cohen C. Survivin and caspase-3 expression in breast cancer: Correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl. Immunohistochem. Mol. Morphol. 2008;16:113\u2013120. doi: 10.1097/PAI.0b013e318032ea73.", "ArticleIdList": ["10.1097/PAI.0b013e318032ea73", "18227733"]}, {"Citation": "Cui Q., Yu J.H., Wu J.N., Tashiro S.I., Onodera S., Minami M., Ikejima T. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol. Sin. 2007;28:1057\u20131066. doi: 10.1111/j.1745-7254.2007.00588.x.", "ArticleIdList": ["10.1111/j.1745-7254.2007.00588.x", "17588343"]}, {"Citation": "O\u2019Donovan N., Crown J., Stunell H., Hill A.D., McDermott E., O\u2019Higgins N., Duffy M.J. Caspase 3 in breast cancer. Clin. Cancer Res. 2003;9:738\u2013742.", "ArticleIdList": ["12576443"]}, {"Citation": "Abbas T., Dutta A. p21 in cancer: Intricate networks and multiple activities. Nat. Rev. Cancer. 2009;9:400\u2013414. doi: 10.1038/nrc2657.", "ArticleIdList": ["10.1038/nrc2657", "PMC2722839", "19440234"]}, {"Citation": "Thomadaki H., Scorilas A. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect. Tissue Res. 2008;49:261\u2013264. doi: 10.1080/03008200802147829.", "ArticleIdList": ["10.1080/03008200802147829", "18661356"]}, {"Citation": "Luna-Vargas M.P.A., Chipuk J.E. Physiological and Pharmacological Control of BAK, BAX, and Beyond. Trends Cell Biol. 2016;26:906\u2013917. doi: 10.1016/j.tcb.2016.07.002.", "ArticleIdList": ["10.1016/j.tcb.2016.07.002", "PMC5118054", "27498846"]}, {"Citation": "Da Veiga G.L., da Silva RD M., Pereira E.C., Azzalis L.A., da Costa Aguiar Alves B., de Sousa Gehrke F., Gasc\u00f3n T.M., Fonseca F.L.A. The role of Survivin as a biomarker and potential prognostic factor for breast cancer. Rev. Assoc. Med. Bras. 2019;65:893\u2013901. doi: 10.1590/1806-9282.65.6.893.", "ArticleIdList": ["10.1590/1806-9282.65.6.893", "31340322"]}, {"Citation": "Motawi T.M.K., Zakhary N.I., Darwish H.A., Abdalla H.M., Tadros S.A. Significance of Serum Survivin and -31G/C Gene Polymorphism in the Early Diagnosis of Breast Cancer in Egypt. Clin. Breast Cancer. 2019;19:e276\u2013e282. doi: 10.1016/j.clbc.2019.01.002.", "ArticleIdList": ["10.1016/j.clbc.2019.01.002", "30765238"]}, {"Citation": "Feng F.F., Zhang D.R., Tian K.L., Lou H.Y., Qi X.L., Wang Y.C., Duan C.X., Jia L.J., Wang F.H., Liu Y., et al. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension. Drug Deliv. 2011;18:265\u2013271. doi: 10.3109/10717544.2010.536271.", "ArticleIdList": ["10.3109/10717544.2010.536271", "21091387"]}, {"Citation": "Kumar A., D\u2019Souza S.S., Gaonkar S.L., Rai K.L., Salimath B.P. Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by a new series of substituted-1,3,4-oxadiazole derivatives. Investig. New Drugs. 2008;26:425\u2013435. doi: 10.1007/s10637-008-9116-5.", "ArticleIdList": ["10.1007/s10637-008-9116-5", "18227972"]}, {"Citation": "J\u00e4nicke R.U., Sprengart M.L., Wati M.R., Porter A.G. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J. Biol. Chem. 1998;273:9357\u20139360. doi: 10.1074/jbc.273.16.9357.", "ArticleIdList": ["10.1074/jbc.273.16.9357", "9545256"]}, {"Citation": "Jiang H., Fan D., Zhou G., Li X., Deng H. Phosphatidylinositol 3-kinase inhibitor(LY294002) induces apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J. Exp. Clin. Cancer Res. 2010;29:34. doi: 10.1186/1756-9966-29-34.", "ArticleIdList": ["10.1186/1756-9966-29-34", "PMC2873422", "20412566"]}, {"Citation": "Post A.E.M., Bussink J., Sweep F.C., Span P.N. Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer. Oncol. Res. 2020;28:33\u201340. doi: 10.3727/096504019X15555794826018.", "ArticleIdList": ["10.3727/096504019X15555794826018", "PMC7851527", "31046897"]}, {"Citation": "Andre F., Nahta R., Conforti R., Boulet T., Aziz M., Yuan LX H., Meslin F., Spielmann M., Tomasic G., Pusztai L., et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann. Oncol. 2008;19:315\u2013320. doi: 10.1093/annonc/mdm429.", "ArticleIdList": ["10.1093/annonc/mdm429", "17804473"]}, {"Citation": "Yang Z.Y., Di M.Y., Yuan J.Q., Shen W.X., Zheng D.Y., Chen J.Z., Mao C., Tang J.L. The prognostic value of phosphorylated Akt in breast cancer: A systematic review. Sci. Rep. 2015;5:7758. doi: 10.1038/srep07758.", "ArticleIdList": ["10.1038/srep07758", "PMC4291578", "25582346"]}, {"Citation": "Alkahtani H.M., Abdalla A.N., Obaidullah A.J., Alanazi M.M., Almehizia A.A., Alanazi M.G., Ahmed A.Y., Alwassil O.I., Darwish H.W., Abdel-Aziz A.A.-M., et al. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2. Bioorg. Chem. 2020;95:103461. doi: 10.1016/j.bioorg.2019.103461.", "ArticleIdList": ["10.1016/j.bioorg.2019.103461", "31838290"]}, {"Citation": "Gouda A.M., Abdelazeem A.H., Abdalla A.N., Ahmed M. Pyrrolizine-5-carboxamides: Exploring the impact of various substituents on anti-inflammatory and anticancer activities. Acta Pharm. 2018;68:251\u2013273. doi: 10.2478/acph-2018-0026.", "ArticleIdList": ["10.2478/acph-2018-0026", "31259695"]}, {"Citation": "Fall A.D., Bagla VP B., Bassene E., Eloff J.N. Phytochemical Screening, Antimicrobial and Cytotoxicity Studies of Ethanol Leaf Extract of Aphaniasenegalensis (Sapindaceae) Afr. J. Tradit. Complement. Altern. Med. 2017;14:135\u2013139. doi: 10.21010/ajtcam.v14i4.16.", "ArticleIdList": ["10.21010/ajtcam.v14i4.16", "PMC5471460", "28638876"]}, {"Citation": "Abdalla A.N., Shaheen U., Abdallah Q., Flamini G., Bkhaitan M.M., Abdelhady M.I., Ascrizzi R., Bader A. Proapoptotic Activity of Achillea membranacea Essential Oil and Its Major Constituent 1,8-Cineole against A2780 Ovarian Cancer Cells. Molecules. 2020;25:1582. doi: 10.3390/molecules25071582.", "ArticleIdList": ["10.3390/molecules25071582", "PMC7180961", "32235558"]}, {"Citation": "Malki W.H., Gouda A.M., Ali H.E., Al-Rousan R., Samaha D., Abdalla A.N., Bustamante J., Elmageed Z.Y.A., Ali H.I. Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition. Eur. J. Med. Chem. 2018;152:31\u201352. doi: 10.1016/j.ejmech.2018.04.029.", "ArticleIdList": ["10.1016/j.ejmech.2018.04.029", "29684708"]}, {"Citation": "Abdalla A.N., Abdallah M.E., Aslam A., Bader A., Vassallo A., De Tommasi N., Malki W.H., Gouda A.M., Mukhtar M.H., El-Readi M.Z., et al. Synergistic Anti Leukemia Effect of a Novel Hsp90 and a Pan Cyclin Dependent Kinase Inhibitors. Molecules. 2020;25:2220. doi: 10.3390/molecules25092220.", "ArticleIdList": ["10.3390/molecules25092220", "PMC7248782", "32397330"]}, {"Citation": "Shaheen U., Ragab E.A., Abdalla A.N., Bader A. Triterpenoidal saponins from the fruits of Gleditsia caspica with proapoptotic properties. Phytochemistry. 2018;145:168\u2013178. doi: 10.1016/j.phytochem.2017.11.007.", "ArticleIdList": ["10.1016/j.phytochem.2017.11.007", "29156366"]}]}], "History": [{"Year": "2020", "Month": "6", "Day": "27"}, {"Year": "2020", "Month": "7", "Day": "18"}, {"Year": "2020", "Month": "7", "Day": "21"}, {"Year": "2020", "Month": "7", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "2", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["32722075", "PMC7436112", "10.3390/molecules25153355", "molecules25153355"]}}]}